New LaunchJun 9, 2026, 08:06 AM
Scienture's REZENOPY™ gains national health plan coverage for 100M+ lives
AI Summary
Scienture Holdings announced that REZENOPY™ (naloxone HCl) Nasal Spray 10 mg has been added to a large national health plan's formulary, extending potential coverage to over 100 million lives ahead of its mid-July 2026 commercial launch. This expands access for the highest FDA-approved naloxone dose, targeting the ~$144 million U.S. naloxone market. The company has also secured GPO agreements covering over 5,000 healthcare facilities and expanded its sales team to support nationwide rollout.
Key Highlights
- REZENOPY™ added to a large national health plan formulary, covering over 100 million lives.
- Commercial launch of REZENOPY™ (naloxone HCl) Nasal Spray 10 mg planned for mid-July 2026.
- U.S. naloxone market totals ~$144 million in annual sales and ~9.8 million units annually.
- GPO agreements provide commercial access for REZENOPY™ across more than 5,000 healthcare facilities.
- GPO agreements create potential to penetrate over 60% of the U.S. institutional naloxone market.
- Scienture expanded its commercial organization with three new sales representatives.
- REZENOPY™ is the highest FDA-approved naloxone dose (10 mg) per nasal spray available.
Price Impact
More from SCNX